Abilify Approved as Additional Treatment for Major Depression

Apocalypse Suicide Page
Good Mood
Living with Depression
Mental Health Recovery
NIMH
SHOCKED! ECT

HealthyPlace.com Radio
Depression Support Groups

Books on Depression
Conference Transcripts
Depression Videos
Diaries - Journals
Disorders Definitions
Mental Health News
Online Depression Tests
Psychiatric Medications
Resources
Site Map

Email
ICQ
Instant Messenger

Visit and Post

Abuse
ADD/ADHD
Addictions
Anxiety-Panic
Bipolar
Eating Disorders
Personality Disorders
Self-Injury

send this page to a friend

Abilify Approved as Additional Treatment for Major Depression

When antidepressant therapy isn't enough

(November 20, 2007) -- (HealthDay News) -- The U.S. Food and Drug Administration has approved the Bristol-Myers drug Abilify (aripiprazole) as an add-on therapy for people with major depressive disorder who don't benefit enough from antidepressant therapy alone, the drug maker said Tuesday.

Abilify, approved in November 2002 to treat schizophrenia, is among a class of medications called atypical antipsychotics. The latest approval followed clinical studies involving 743 patients.

Elderly people with dementia-related psychosis who are treated with atypical antipsychotics are at greater risk of death, Bristol-Myers warned in a statement.

Side effects of Abilify may include akathisia -- a syndrome characterized by feelings of inner restlessness and the urge to move. Other "adverse events" reported among clinical users included insomnia, constipation, fatigue, and blurred vision, the company said.

Abilify is co-marketed by Otsuka Pharmaceutical Co. of Japan.

Source: HealthDay News

Last updated: 11/07

Abilify Approved as Additional Treatment for Major Depression

Related Stories